OBJECTIVE: We investigated whether preventing hyperglycemia in septic patients affected the plasma concentration of asymmetric-dimethylarginine and if this was associated with clinical benefit. DESIGN: A prospective, multicenter, randomized, controlled, clinical study. SETTING:Intensive care units (ICU) in three university hospitals. PATIENTS: A total of 72 patients admitted for severe sepsis or septic shock, who stayed at least 3 days in the ICU. At admission the patients were assigned to receive either tight or conventional glycemic control. INTERVENTIONS:Determination of circulating levels of asymmetric-dimethylarginine, arginine, interleukin-6, C-reactive-protein and tumor-necrosis-factor-alpha. MEASUREMENTS AND RESULTS: Blood was sampled at admission (no differences between groups), and on the 3rd, 6th, 9th, and 12th (T12) days. Sequential organ failure assessment was scored at each sampling time. All the data were analyzed on an intention-to-treat basis. The control and treatment groups received the same energy intake, glycemia (110.4 +/- 17.3 vs. 163.0 +/- 28.9 mg/dL, P < 0.001) and insulin (P = 0.02) supply differed. No differences were found in high plasma levels of asymmetric-dimethylarginine (P = 0.812) at any time during the ICU stay. The clinical course, as indicated by markers of inflammation, average and maximum organ failure score, ICU stay and ICU and 90-day mortality, was the same. CONCLUSIONS: Intensive insulin treatment, while achieving glucose control, did not reduce asymmetric-dimethylarginine in high-risk septic patients fed with no more than 25 kcal/kg per day to limit ventilatory demand and to simplify glucose control. DESCRIPTOR: 45 (SIRS/sepsis: clinical studies).
RCT Entities:
OBJECTIVE: We investigated whether preventing hyperglycemia in septic patients affected the plasma concentration of asymmetric-dimethylarginine and if this was associated with clinical benefit. DESIGN: A prospective, multicenter, randomized, controlled, clinical study. SETTING: Intensive care units (ICU) in three university hospitals. PATIENTS: A total of 72 patients admitted for severe sepsis or septic shock, who stayed at least 3 days in the ICU. At admission the patients were assigned to receive either tight or conventional glycemic control. INTERVENTIONS: Determination of circulating levels of asymmetric-dimethylarginine, arginine, interleukin-6, C-reactive-protein and tumor-necrosis-factor-alpha. MEASUREMENTS AND RESULTS: Blood was sampled at admission (no differences between groups), and on the 3rd, 6th, 9th, and 12th (T12) days. Sequential organ failure assessment was scored at each sampling time. All the data were analyzed on an intention-to-treat basis. The control and treatment groups received the same energy intake, glycemia (110.4 +/- 17.3 vs. 163.0 +/- 28.9 mg/dL, P < 0.001) and insulin (P = 0.02) supply differed. No differences were found in high plasma levels of asymmetric-dimethylarginine (P = 0.812) at any time during the ICU stay. The clinical course, as indicated by markers of inflammation, average and maximum organ failure score, ICU stay and ICU and 90-day mortality, was the same. CONCLUSIONS: Intensive insulin treatment, while achieving glucose control, did not reduce asymmetric-dimethylarginine in high-risk septic patients fed with no more than 25 kcal/kg per day to limit ventilatory demand and to simplify glucose control. DESCRIPTOR: 45 (SIRS/sepsis: clinical studies).
Authors: Jan T Kielstein; Stefanie M Bode-Böger; Gerrit Hesse; Jens Martens-Lobenhoffer; Attila Takacs; Danilo Fliser; Marius M Hoeper Journal: Arterioscler Thromb Vasc Biol Date: 2005-04-28 Impact factor: 8.311
Authors: C Zoccali; S Bode-Böger; F Mallamaci; F Benedetto; G Tripepi; L Malatino; A Cataliotti; I Bellanuova; I Fermo; J Frölich; R Böger Journal: Lancet Date: 2001 Dec 22-29 Impact factor: 79.321
Authors: B Marescau; G Nagels; I Possemiers; M E De Broe; I Becaus; J M Billiouw; W Lornoy; P P De Deyn Journal: Metabolism Date: 1997-09 Impact factor: 8.694
Authors: Markus C Stühlinger; Roberta K Oka; Eric E Graf; Isabella Schmölzer; Barbara M Upson; Om Kapoor; Andrzej Szuba; M Rene Malinow; Thomas C Wascher; Otmar Pachinger; John P Cooke Journal: Circulation Date: 2003-08-11 Impact factor: 29.690
Authors: R J Nijveldt; T Teerlink; B Van Der Hoven; M P C Siroen; D J Kuik; J A Rauwerda; P A M van Leeuwen Journal: Clin Nutr Date: 2003-02 Impact factor: 7.324
Authors: Michael J O'Dwyer; Felicity Dempsey; Vivion Crowley; Dermot P Kelleher; Ross McManus; Thomas Ryan Journal: Crit Care Date: 2006 Impact factor: 9.097
Authors: Anna Bryland; Marcus Broman; Martin Erixon; Bengt Klarin; Torbjörn Lindén; Hans Friberg; Anders Wieslander; Per Kjellstrand; Claudio Ronco; Ola Carlsson; Gabriela Godaly Journal: Intensive Care Med Date: 2010-04-16 Impact factor: 17.440
Authors: Donald E G Griesdale; Russell J de Souza; Rob M van Dam; Daren K Heyland; Deborah J Cook; Atul Malhotra; Rupinder Dhaliwal; William R Henderson; Dean R Chittock; Simon Finfer; Daniel Talmor Journal: CMAJ Date: 2009-03-24 Impact factor: 8.262